TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB PLUS AROMATASE INHIBITOR OR PALBOCICLIB PLUS FULVESTRANT AS TREATMENT OF HORMONE RECEPTOR POSITIVE (HR+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN A REAL WORLD COMMUNITY ONCOLOGY SETTING
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10017
- Pfizer United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients who are represented in the Vector Oncology Data Warehouse who meet all of the following criteria will be eligible for inclusion in the study.
- Female.
- Diagnosis of female breast cancer with evidence of metastatic disease or advanced disease.
- Diagnosis (confirmed by clinical review) of advanced or metastatic breast cancer at any time, defined as breast cancer at stage IIIb, stage IIIc, or stage IV or identified as having distant metastasis.
- Indication in the record of ER or PR positive disease, or absence of any indication of ER and PR negative disease (ie, patients are eligible without affirmative indication of ER/PR+ status as long as ER/PR- indication is not present).
- Receipt of a palbociclib plus aromatase inhibitor (AI) or palbociclib plus fulvestrant regimen on 2/3/2015 or later in the advanced and metastatic setting. Data collection will prioritize accrual of patients with 1L use of palbociclib plus AI and with 2L use of palbociclib plus fulvestrant before collecting other use of palbociclib users.
- Age greater than or equal to 18 years at A/MBC diagnosis.
Exclusion Criteria:
-There are no exclusion criteria for this study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Breast cancer patients
HR+/HER2- advanced/metastatic breast cancer patients in the USA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients receiving various cancer treatment regimens
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Proportion of patients receiving each therapy sequence across lines
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Treatment persistence
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Progression Free Survival (PFS)
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Overall Survival (OS)
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Tumor response rate
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Proportion of patients that experience dose adjustment
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
|
Proportion of patients who discontinue therapy
Time Frame: A/MBC diagnosis through end of study (assessed up to 24 months)
|
A/MBC diagnosis through end of study (assessed up to 24 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5481095
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.